Lisata Therapeutics (NASDAQ:LSTA) Trading Down 3.6% – Should You Sell?

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was down 3.6% during mid-day trading on Thursday . The company traded as low as $2.06 and last traded at $2.12. 54,171 shares were traded during mid-day trading, a decline of 25% from the average daily volume of 71,772 shares. The stock had previously closed at $2.20.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lisata Therapeutics in a report on Friday, July 17th. Zacks Research raised Lisata Therapeutics to a “hold” rating in a research note on Monday, May 18th. Finally, HC Wainwright downgraded Lisata Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 15th. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $15.00.

Lisata Therapeutics Trading Down 3.6%

The company’s 50-day moving average is $3.32 and its 200 day moving average is $3.78. The firm has a market cap of $19.31 million, a PE ratio of -1.14 and a beta of 0.79.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.50) earnings per share for the quarter. On average, research analysts predict that Lisata Therapeutics, Inc. will post -1.09 EPS for the current fiscal year.

Institutional Trading of Lisata Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Cerity Partners LLC purchased a new position in shares of Lisata Therapeutics during the second quarter valued at $32,000. CIBC Bancorp USA Inc. acquired a new position in Lisata Therapeutics during the third quarter valued at $37,000. SOL Capital Management CO purchased a new stake in Lisata Therapeutics in the 1st quarter worth about $61,000. Ground Swell Capital LLC lifted its stake in Lisata Therapeutics by 64.0% in the 4th quarter. Ground Swell Capital LLC now owns 38,987 shares of the company’s stock worth $73,000 after acquiring an additional 15,213 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in Lisata Therapeutics by 6.1% during the 4th quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock worth $230,000 after acquiring an additional 7,093 shares during the period. Institutional investors and hedge funds own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.